The prognostic value of ASXL1 mutation in primary myelofibrosis. Literature review and clinical case description

The prognostic value of ASXL1 mutation in primary myelofibrosis. Literature review and clinical case description

Primary myelofibrosis is a myeloproliferative neoplasm that occurs de novo, characterized by clonal proliferation of stem cells, abnormal expression of cytokines, bone marrow fibrosis, hepatosplenomegaly as a result of extramedullary hematopoiesis, symptoms of tumor intoxication, cachexemia, periph...

Full description

Bibliographic Details
Main Authors:	A. L. Melikyan, I. N. Subortseva, E. A. Gilyazitdinova, T. I. Koloshejnova, E. K. Egorova, E. I. Pustovaya, A. B. Sudarikov, A. O. Abdullaev, L. A. Gorgidze, D. I. Chebotarev
Format:	Article
Language:	Russian
Published:	"Consilium Medicum" Publishing house 2020-09-01
Series:	Терапевтический архив
Subjects:	primary myelofibrosis myeloproliferative neoplasms asxl1 mutations allogeneic stem cell transplantation
Online Access:	https://ter-arkhiv.ru/0040-3660/article/viewFile/43132/pdf

Similar Items

Thrombosis in patients with myeloproliferative neoplasms. Case report
by: Anait L. Melikyan, et al.
Published: (2021-07-01)

The Genetic Basis of Primary Myelofibrosis and Its Clinical Relevance
by: Elisa Rumi, et al.
Published: (2020-11-01)

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease
by: A L Melikyan, et al.
Published: (2017-07-01)

Characterization of engraftment dynamics in myelofibrosis after allogeneic hematopoietic cell transplantation including novel conditioning schemes
by: Sarah Jungius, et al.
Published: (2023-08-01)

Molecular Genetic Profile of Myelofibrosis: Implications in the Diagnosis, Prognosis, and Treatment Advancements
by: Tanvi Verma, et al.
Published: (2024-01-01)

Risk factors affect accurate prognosis in ASXL1-mutated acute myeloid leukemia
by: Yi Fan, et al.
Published: (2021-10-01)

Analysis of somatic mutations in the <i>JAK2</i>, <i>CALR</i>, <i>MPL</i> and <i>ASXL1</i> genes and evaluation of their impact on the survival of patients with myelofibrosis
by: T. N. Subbotina, et al.
Published: (2023-03-01)

Young woman with mild bone marrow dysplasia, GATA2 and ASXL1 mutation treated with allogeneic hematopoietic stem cell transplantation
by: Anna Lübking, et al.
Published: (2015-01-01)

Disseminated tuberculosis with myelofibrosis presentation: a case report
by: Mahdi Khatuni, et al.
Published: (2021-11-01)

Clinical features and diagnosis of Ph - negative myeloproliferative neoplasms occurring in conjunction with the antiphospholipid syndrome
by: A L Melikyan, et al.
Published: (2019-07-01)

Mutations in <it>ASXL1 </it>are associated with poor prognosis across the spectrum of malignant myeloid diseases
by: Gelsi-Boyer Véronique, et al.
Published: (2012-03-01)

Non-driver mutations in myeloproliferative neoplasm-associated myelofibrosis
by: Bing Li, et al.
Published: (2017-05-01)

Splanchnic Vein Thrombosis in Myelofibrosis—An Underappreciated Hallmark of Disease Phenotype
by: Elina A. Beleva
Published: (2023-10-01)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2020-08-01)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
by: Naveen Pemmaraju, et al.
Published: (2022-11-01)

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety
by: Srdan Verstovsek, et al.
Published: (2023-07-01)

New Markers of Disease Progression in Myelofibrosis
by: Rita Campanelli, et al.
Published: (2021-10-01)

Primary myelofibrosis: current therapeutic options
by: Paula de Melo Campos

Focus on Osteosclerotic Progression in Primary Myelofibrosis
by: Mariarita Spampinato, et al.
Published: (2021-01-01)

Examining the neurodevelopmental and motor phenotypes of Bohring-Opitz syndrome (ASXL1) and Bainbridge-Ropers syndrome (ASXL3)
by: Maya C. Ayoub, et al.
Published: (2023-11-01)

Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling
by: Samuel B. Reynolds, et al.
Published: (2023-09-01)

ASXL gain-of-function truncation mutants: defective and dysregulated forms of a natural ribosomal frameshifting product?
by: Adam M. Dinan, et al.
Published: (2017-10-01)

Primary myelofibrosis: spectrum of imaging features and disease-related complications
by: Sheng Fei Oon, et al.
Published: (2019-08-01)

Murine Models of Myelofibrosis
by: Sebastien Jacquelin, et al.
Published: (2020-08-01)

JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis
by: Andrew T. Kuykendall, et al.
Published: (2021-08-01)

Janus kinase V617F mutation detection in patients with myelofibrosis
by: Nikolova D, et al.
Published: (2019-08-01)

SPECTRUM OF AFFECTED GENES IN UKRAINIAN PATIENTS WITH PRIMARY MYELOFIBROSIS
by: Poluben L., et al.
Published: (2018-12-01)

Transcription factor 3 is dysregulated in megakaryocytes in myelofibrosis
by: Ryan J Collinson, et al.
Published: (2024-12-01)

Management of myelofibrosis during pregnancy: A case report
by: Živković Radmila, et al.
Published: (2015-01-01)

Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms
by: Eylem Eliaçık, et al.
Published: (2015-05-01)

Mutation profile in Indian primary myelofibrosis patients and its clinical implications
by: Vinod R Patil, et al.
Published: (2019-01-01)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
by: Maria Zingariello, et al.
Published: (2020-11-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)

Advances in management of primary myelofibrosis and polycythaemia vera: Implications in clinical practice
by: Shanti Amé, et al.
Published: (2023-08-01)

The Role of New Technologies in Myeloproliferative Neoplasms
by: Giuseppe A. Palumbo, et al.
Published: (2019-04-01)

The Use of Allogeneic Hematopoietic Stem Cell Transplantation in Primary Myelofibrosis
by: Heather R. Wolfe, et al.
Published: (2022-04-01)

Clinical characteristics and prognosis analysis of patients with de novo ASXL1‐mutated AML treated with the C‐HUNAN‐AML‐15 protocol: A multicenter study by the South China Pediatric AML Collaborative Group
by: Minhui Zeng, et al.
Published: (2023-06-01)

Clinical Characteristics and Outcomes of Patients with Primary and Secondary Myelofibrosis According to the Genomic Classification Using Targeted Next-Generation Sequencing
by: Marta Garrote, et al.
Published: (2023-07-01)

CLINICAL AND LABORATORY FEATURES OF ESSENTIAL THROMBOCYTOSIS AND PRIMARY MYELOFIBROSIS DEPENDING ON JAK2 AND CALR1 MUTATION STATUS
by: E. G. lisina, et al.
Published: (2017-10-01)